{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:21:24Z","timestamp":1793744484196,"version":"4.6.1"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Importance<\/jats:title>\n Biological staging of Alzheimer disease (AD) can improve diagnostic accuracy and prognostic assessment. However, existing approaches often require invasive procedures and specialized infrastructure, limiting their routine clinical use.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop and validate a plasma-based biological staging model that closely mirrors an amyloid and tau positron emission tomography (PET)\u2013based staging system.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This observational longitudinal study included the research BioFINDER-2 cohort as the main cohort and the Knight Alzheimer Disease Research Center (ADRC) cohort as an independent validation cohort, with data acquired from November 2019 to January 2025 and from September 2007 to March 2020, respectively. Participants ranged from cognitively unimpaired (CU) to experiencing mild cognitive impairment (MCI) and dementia with AD or other neurodegenerative diseases. All individuals had both plasma biomarkers available. A Knight ADRC subsample had neuropathological data available. Data were analyzed from December 2024 to July 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Plasma endogenously cleaved microtubule-binding region tau containing residue 243 (eMTBR-tau243) and phosphorylated tau at threonine 217 expressed as a percentage of its unphosphorylated form (%p-tau217).<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcomes were PET-based biological staging according to the revised Alzheimer\u2019s Association criteria, clinical criteria, and biomarker levels assessed cross-sectionally and longitudinally.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The BioFINDER-2 main cohort included 872 participants, with an additional 156 participants in the Knight ADRC cohort for independent validation. In the BioFINDER-2 cohort, participants included 383 CU participants, 182 participants with MCI, 151 with AD dementia, and 156 participants with non-AD neurogenerative diseases (mean [SD] age, 72.8 [9.2] years; 438 women [50.2%]; 516 [59.2%] apolipoprotein E [\n APOE-E4<\/jats:italic>\n ] carriers). A plasma-based model with %p-tau217 and eMTBR-tau243 was derived, which demonstrated high concordance with established PET-based stages (C index, 0.91; 95% CI, 0.90-0.92) and was associated with clinical stage within the AD continuum (C index, 0.84; 95% CI, 0.82-0.86). In the validation cohort, concordance with PET-based stages was high (C index, 0.91; 95% CI, 0.87-0.94), as was concordance with clinical stage (C index, 0.86; 95% CI, 0.82-0.89). Concordance between fluid- and PET-based staging models was higher with this study\u2019s %p-tau217 and eMTBR-tau243 model than with a staging model using %p-tau217 alone, especially improving the intermediate or C stage (A+T\n MOD<\/jats:sub>\n +) classification. In the neuropathology subsample, plasma staging was strongly aligned with autopsy-confirmed AD pathology using the Alzheimer Disease Neuropathologic Change scale (area under the curve, 0.96; 95% CI, 0.91-1.00).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this longitudinal study, a plasma-based biological staging model incorporating %p-tau217 and eMTBR-tau243 showed strong concordance with PET-based staging, correlated with clinical severity and biomarker progression, and aligned with neuropathological categorization. This scalable, minimally invasive approach could facilitate broader implementation of biological staging in clinical practice and could enhance participant selection for disease-modifying treatments and clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.1405","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:00:25Z","timestamp":1779807625000},"page":"654","source":"Crossref","is-referenced-by-count":7,"title":["Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease"],"prefix":"10.1001","volume":"83","author":[{"given":"Gemma","family":"Salvad\u00f3","sequence":"first","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Barcelona\u03b2eta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Horie","sequence":"additional","affiliation":[{"name":"The Tracy Family SILQ Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"},{"name":"Eisai Inc, Nutley, New Jersey"},{"name":"Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas R.","family":"Barth\u00e9lemy","sequence":"additional","affiliation":[{"name":"The Tracy Family SILQ Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"},{"name":"Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ordu\u00f1a Dolado","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Bali","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Perrin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"},{"name":"Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, Missouri"},{"name":"Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"},{"name":"Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammie L. S.","family":"Benzinger","sequence":"additional","affiliation":[{"name":"Department of Radiology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Radiology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[{"name":"SciLifeLab, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[{"name":"The Tracy Family SILQ Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"},{"name":"Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Alzheimer Center Amsterdam, Neurology, Amsterdam UMC location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Neurodegeneration, Amsterdam Neuroscience, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"noi260028r1","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup.","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"7","key":"noi260028r2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaneurol.2025.1100","article-title":"Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.","volume":"82","author":"Pichet Binette","year":"2025","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi260028r3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"noi260028r4","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer\u2019s disease drug development pipeline: 2024.","volume":"10","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"noi260028r5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","article-title":"Biomarker-based staging of Alzheimer disease: rationale and clinical applications.","volume":"20","author":"Therriault","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"noi260028r6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","article-title":"A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.","volume":"148","author":"Warmenhoven","year":"2025","journal-title":"Brain"},{"issue":"11","key":"noi260028r7","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology.","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi260028r8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests.","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"issue":"15","key":"noi260028r9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care.","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"noi260028r10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies.","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi260028r11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s43856-025-00768-z","article-title":"Alzheimer\u2019s disease biological PET staging using plasma p217+tau.","volume":"5","author":"Feizpour","year":"2025","journal-title":"Commun Med (Lond)"},{"issue":"5","key":"noi260028r12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads.","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"9","key":"noi260028r13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","article-title":"Blood phosphorylated tau for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"24","author":"Therriault","year":"2025","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi260028r14","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease.","volume":"29","author":"Horie","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"noi260028r15","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease.","volume":"31","author":"Horie","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"noi260028r16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"noi260028r17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","article-title":"CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease.","volume":"3","author":"Barth\u00e9lemy","year":"2023","journal-title":"Nat Aging"},{"key":"noi260028r18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","article-title":"AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure.","volume":"161","author":"Mishra","year":"2017","journal-title":"Neuroimage"},{"issue":"1","key":"noi260028r19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.dadm.2018.12.008","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.","volume":"11","author":"Su","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"noi260028r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"2","key":"noi260028r21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","article-title":"Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.","volume":"47","author":"Smith","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"noi260028r22","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"noi260028r23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnmt.123.267113","article-title":"Improved correlation of 18F-flortaucipir PET SUVRs and clinical stages in the Alzheimer disease continuum with the MUBADA\/PERSI-based analysis.","volume":"52","author":"Ikari","year":"2024","journal-title":"J Nucl Med Technol"},{"issue":"Pt 12","key":"noi260028r24","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1093\/brain\/awv283","article-title":"Different definitions of neurodegeneration produce similar amyloid\/neurodegeneration biomarker group findings.","volume":"138","author":"Jack","year":"2015","journal-title":"Brain"},{"issue":"8","key":"noi260028r25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi260028r26","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1002\/alz.14253","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative Neuropathology Core: an update.","volume":"20","author":"Perrin","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi260028r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach.","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"8","key":"noi260028r28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jnen\/nly049","article-title":"The revised National Alzheimer\u2019s Coordinating Center\u2019s Neuropathology Form-available data and new analyses.","volume":"77","author":"Besser","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"noi260028r29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","article-title":"Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model.","volume":"4","author":"Salvad\u00f3","year":"2024","journal-title":"Nat Aging"},{"issue":"3","key":"noi260028r31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology.","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi260028r32","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease.","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"noi260028r33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). part II. standardization of the neuropathologic assessment of Alzheimer\u2019s disease.","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"noi260028r34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes.","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"noi260028r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform.","volume":"109","author":"Feizpour","year":"2024","journal-title":"EBioMedicine"},{"issue":"5","key":"noi260028r36","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","article-title":"Predicting amyloid PET and tau PET stages with plasma biomarkers.","volume":"146","author":"Jack","year":"2023","journal-title":"Brain"},{"issue":"10","key":"noi260028r37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","article-title":"Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment.","volume":"79","author":"Strikwerda-Brown","year":"2022","journal-title":"JAMA Neurol"},{"issue":"10","key":"noi260028r38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain \u00df-amyloid load approaches a plateau.","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"noi260028r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104450","article-title":"Rates of regional tau accumulation in ageing and across the Alzheimer\u2019s disease continuum: an AIBL 18F-MK6240 PET study.","volume":"88","author":"Krishnadas","year":"2023","journal-title":"EBioMedicine"},{"issue":"12","key":"noi260028r40","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1093\/brain\/awaa327","article-title":"The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.","volume":"143","author":"Smith","year":"2020","journal-title":"Brain"},{"issue":"3","key":"noi260028r41","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/brain\/awaf346","article-title":"Staging Alzheimer\u2019s disease through amyloid and tau PET.","volume":"149","author":"Johnson","year":"2026","journal-title":"Brain"},{"issue":"9","key":"noi260028r42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.molmed.2022.05.008","article-title":"Staging of Alzheimer\u2019s disease: past, present, and future perspectives.","volume":"28","author":"Therriault","year":"2022","journal-title":"Trends Mol Med"},{"issue":"6","key":"noi260028r43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging.","volume":"2","author":"Therriault","year":"2022","journal-title":"Nat Aging"},{"issue":"11","key":"noi260028r44","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","article-title":"Multitracer model for staging cortical amyloid deposition using PET imaging.","volume":"95","author":"Collij","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"noi260028r45","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s43587-025-00951-w","article-title":"Plasma tau biomarkers for biological staging of Alzheimer\u2019s disease.","volume":"5","author":"Montoliu-Gaya","year":"2025","journal-title":"Nat Aging"},{"issue":"11","key":"noi260028r46","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u00df PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts.","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"5","key":"noi260028r47","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2967\/jnumed.120.245423","article-title":"What Is T+? a Gordian knot of tracers, thresholds, and topographies.","volume":"62","author":"Villemagne","year":"2021","journal-title":"J Nucl Med"},{"key":"noi260028r30","author":"Lundberg","year":"2017"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2849574\/jamaneurology_salvad_2026_oi_260028_1782409418.42008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:00:27Z","timestamp":1783954827000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2849574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.1405","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}